Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Essen
About this trial
This study seeks to explore the possible common pathogenesis of both cardiac amyloidosis and Alzheimer's disease, which can both be associated with amyloid deposits. Using Positron Emission Tomography (PET) scans with amyloid tracers - a conventional tool for non-invasively imaging amyloid deposits in Alzheimer's disease - the research will extend this imaging methodology to the heart.
The study will conduct additional PET/MRI scans of the heart in patients undergoing amyloid tracer PET scans for Alzheimer's evaluations. Each participant will also undergo an echocardiogram and a clinical examination of dementia.
This could potentially enhance diagnostic practices in both cardiac amyloidosis and Alzheimer's disease.
Eligibility criteria
Qualifiers
Patients undergoing cerebral amyloid PET examination for clinical indication to clarify Alzheimer's disease
No contraindications to undergo an MRI examination
No contraindications to undergo an Amyloid PET scan
Disqualifiers
Patients with vascular dementia and confirmed other causes of dementia (e.g. stroke, vitamin deficiency, thyroid insufficiency, toxic causes such as alcohol)
Patients with pronounced cardiac preconditions
Pregnant and breastfeeding women
Trial design
Treatments tested in this trial
- Not listed
Trial groups
15 Participants
are grouped into 1 trial groupLocations
1University Hospital Essen45147, EssenNorth Rhine-Westphalia, Germany
Sponsors and collaborators
University Hospital, Essen
Lead sponsor
Source ClinicalTrials.gov